Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

This study has been terminated.
Sponsor:
Information provided by:
Wellstat Therapeutics
ClinicalTrials.gov Identifier:
NCT00044785
First received: September 4, 2002
Last updated: June 23, 2005
Last verified: May 2005
  Purpose

CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for colorectal cancer. PN401 permits treatment with higher than normal doses of 5FU, which could increase its therapeutic potential. It is hypothesized that adding PN401 to the CPT-11, 5FU, leucovorin regimen will reduce toxicity and will allow higher doses of 5FU to be well tolerated and therefore potentially increase effectiveness.


Condition Intervention Phase
Solid Tumors
Drug: triacetyluridine
Drug: fluorouracil
Drug: leucovorin
Drug: camptosar
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of Escalating Doses of CPT-11 and 5fluorouracil (5FU) Plus PN401 With a Fixed Dose of Leucovorin in Patients With Solid Tumor Malignancies.

Resource links provided by NLM:


Further study details as provided by Wellstat Therapeutics:

Primary Outcome Measures:
  • Safety and Maximum Tolerated Dose

Estimated Enrollment: 24
Study Start Date: August 2002
Estimated Study Completion Date: March 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Must be at least 18 years of age;
  • Life expectancy: At least 3 months;
  • Performance status: ECOG of 0 or 1;
  • Histologic or cytologic proof of a solid tumor cancer that is not amenable to curative surgical resection;
  • Evaluable or measurable disease documented within 4 weeks of the start of treatment;
  • Prior chemotherapy or radiotherapy is allowed if 4 weeks or more have elapsed prior to starting treatment and patients have recovered from toxicities of prior treatment;
  • Adequate organ function:

Hematopoietic: ANC = 1500/ul or more, Platelets = 100,000/ul or more, Hemoglobin = 9.5 g/dL or more, transfusion prior to evaluation is allowed; Hepatic: Bilirubin = 2.0 mg/dL or less and SGPT(ALT) and SGOT(AST) < 3 x upper limit of normal (< 5 x upper limit of normal if liver metastases present) Renal: Serum Creatinine < 2.0 mg/dL;

  • Patient has the initiative, geographic proximity, and means to be compliant with the protocol;
  • Fertile patients (male or female) must agree to use effective contraception;
  • Must be able to swallow and retain tablets.

Exclusion Criteria

  • Major surgery within the four weeks preceding the start of treatment;
  • Serious medical or psychiatric illness that would prevent self-determined informed consent;
  • Intensive chemotherapy treatment;
  • Infection or antibiotics at the time of screening;
  • Uncontrolled cardiovascular, pulmonary, renal, neurologic, psychiatric, or hepatic dysfunction;
  • Pregnant or nursing;
  • Pre-existing diarrhea or uncontrolled clinically significant illness other than cancer (i.e. ulcerative colitis, malabsorption syndrome);
  • Brain metastases that have not been stable for more than 3 months;
  • Known Dihydropyrimidine Dehydrogenase (DPD) deficiency.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00044785

Locations
United States, Maryland
University of Maryland, Greenebaum Cancer Center
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
Wellstat Therapeutics
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00044785     History of Changes
Other Study ID Numbers: 401.02.001, GCC0121
Study First Received: September 4, 2002
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by Wellstat Therapeutics:
colorectal cancer
gastric cancer
breast cancer

Additional relevant MeSH terms:
Neoplasms
Fluorouracil
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antimetabolites, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 19, 2014